Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study.
Saved in:
| Title: | Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. |
|---|---|
| Authors: | Kirste S; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany., Kroeze SGC; Department of Radiation Oncology, University Hospital Zürich, University of Zurich, Zurich, Switzerland., Henkenberens C; Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany., Schmidt-Hegemann NS; Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Vogel MME; Department of Radiation Oncology, Technical University Munich, Munich, Germany.; Institute of Radiation Medicine (IRM), Helmholtz Zentrum Munich, Oberschleissheim, Germany., Becker J; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany., Zamboglou C; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany., Burger I; Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, Switzerland., Derlin T; Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital LMU Munich, Munich, Germany., Ruf J; Department of Nuclear Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany., la Fougère C; Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tübingen, Tübingen, Germany., Eiber M; Department of Nuclear Medicine, Technical University Munich, Munich, Germany., Christiansen H; Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany., Combs SE; Department of Radiation Oncology, Technical University Munich, Munich, Germany.; Institute of Radiation Medicine (IRM), Helmholtz Zentrum Munich, Oberschleissheim, Germany., Müller AC; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), Partner Site Tübingen, Tübingen, Germany., Belka C; Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Guckenberger M; Department of Radiation Oncology, University Hospital Zürich, University of Zurich, Zurich, Switzerland., Grosu AL; Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. |
| Source: | Frontiers in oncology [Front Oncol] 2021 May 10; Vol. 11, pp. 640467. Date of Electronic Publication: 2021 May 10 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
